LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythe...
Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )
25 Jun 2020
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexame...
Prof Efstathios Kastritis - University of Athens, Athens, Greece
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis ( Prof Efstathios Kastritis - University of Athens, Athens, Greece )
25 Jun 2020
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blina...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymp...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020
Maintenance treatment in multiple myeloma: A new era
Prof Sagar Lonial and Prof Wee-Joo Chng
Maintenance treatment in multiple myeloma: A new era ( Prof Sagar Lonial and Prof Wee-Joo Chng )
18 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )
16 Jun 2020
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin l...
Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )
16 Jun 2020
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
15 Jun 2020
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-cla...
Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib ( Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA )
13 Jun 2020
Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neo...
Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany
Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )
13 Jun 2020
Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )
13 Jun 2020